Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?

Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?

There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2012
Автори: Naumnik, W., Naumnik, B., Niewiarowska, K., Ossolinska, M., Chyczewska, E.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2012
Назва видання:Experimental Oncology
Теми:
Original contributions
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/139877
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-139877
record_format dspace
spelling irk-123456789-1398772018-06-22T03:05:47Z Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Naumnik, W. Naumnik, B. Niewiarowska, K. Ossolinska, M. Chyczewska, E. Original contributions There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before chemotherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are significantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A negative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies. 2012 Article Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/139877 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Naumnik, W.
Naumnik, B.
Niewiarowska, K.
Ossolinska, M.
Chyczewska, E.
Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
Experimental Oncology
description There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before chemotherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are significantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A negative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies.
format Article
author Naumnik, W.
Naumnik, B.
Niewiarowska, K.
Ossolinska, M.
Chyczewska, E.
author_facet Naumnik, W.
Naumnik, B.
Niewiarowska, K.
Ossolinska, M.
Chyczewska, E.
author_sort Naumnik, W.
title Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_short Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_full Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_fullStr Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_full_unstemmed Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
title_sort novel cytokines: il-27, il-29, il-31 and il-33. can they be useful in clinical practice at the time diagnosis of lung cancer?
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2012
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/139877
citation_txt Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT naumnikw novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT naumnikb novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT niewiarowskak novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT ossolinskam novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
AT chyczewskae novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer
first_indexed 2023-10-18T21:20:34Z
last_indexed 2023-10-18T21:20:34Z
_version_ 1796152570743357440

Схожі ресурси